摘要
宫颈癌是严重威胁女性健康的常见妇科恶性肿瘤之一,与人乳头瘤病毒(HPV)的感染密切相关。随着分子生物学与免疫学的发展,免疫治疗成为宫颈癌新的治疗模式。HPV疫苗已在宫颈癌预防方面取得卓越成效。对于传统手术、放化疗治疗不理想的进展期、转移或复发的宫颈癌,多项研究正在探索免疫治疗的安全性、效应性,重组载体疫苗ADXS11-001、抗PD-1单抗Nivolumab、Pembrolizumab等均在前期临床试验中有较好的抗肿瘤效应。目前主要研究方向有局部进展期宫颈癌标准治疗同期或辅助加用免疫治疗,晚期和复发宫颈癌中单药免疫治疗、联合抗血管治疗或多种免疫治疗药物联用,以及新型HPV预防性疫苗的研究。简要综述疫苗免疫治疗、过继细胞治疗、免疫检查点抑制剂和树突细胞免疫治疗等宫颈癌免疫治疗的进展。
Closely related to human papilloma virus(HPV), cervical cancer is one of the most common gynecological malignancies that threatens women′ s health. With the development of molecular biology and immunology, immunotherapy has become a new treatment modality for cervical cancer. HPV vaccines have already achieved remarkable effect in prophylaxis against cervical cancer. Many studies are exploring the safety and efficacy of immunotherapy in advanced, metastatic and recurrent cervical cancer which has dismal prognosis with conventional surgery and chemoradiation. Medications like recombinant vector vaccine ADXS11-001, anti-PD-1 monoclonal antibody Nivolumab and Pembrolizumab are showing promising anti-tumor activity in preliminary clinical trials. At present, researches mainly focus on immunotherapy in concurrent with standard therapy or as adjuvant therapy in locally advanced cervical cancer, mono-immunotherapy or in combination with angiogenesis inhibitor or another immune agent in metastatic and recurrent cervical cancer, and developing novel HPV prophylactic vaccine. This paper briefly reviewed the progress of immunotherapy for cervical cancer from several aspects including vaccine immunotherapy, adoptive cell therapy, immune checkpoint inhibitor and dendritic cell immunotherapy.
出处
《国际妇产科学杂志》
CAS
2017年第6期681-685,共5页
Journal of International Obstetrics and Gynecology
关键词
宫颈肿瘤
癌
免疫疗法
综述
Uterine cervical neoplasms
Carcinoma
Immunotherapy
Review
